ArticleFrontiers in medicine2026
Assessing early therapeutic response in extrapulmonary tuberculosis using [18F]FDG-PET/CT imaging.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Monitoring treatment response in extrapulmonary tuberculosis (EPTB) remains challenging due to limited microbiological accessibility and the lack of validated biomarkers. [18F]FDG positron emission tomography/computed tomography [(18F)FDG-PET/CT] enables assessment of metabolic disease activity and has been explored in infectious diseases, but evidence supporting its use in EPTB is limited. Methods: We conducted a prospective observational study including adults diagnosed with EPTB at a tertiary referral center in Denmark between 2016 and 2018. Participants underwent baseline and follow-up [18F]FDG-PET/CT imaging after completion of the intensive treatment phase. Clinical data and laboratory parameters, including C-reactive protein (CRP), hemoglobin, leukocytes, albumin, and alanine aminotransferase were collected at baseline and during follow-up. Changes in standardized uptake values (SUVmax) and laboratory markers were analyzed descriptively. Results: Seventeen patients were included. Metabolically active disease was detected in all participants at baseline. Most patients (11 out of 14) demonstrated a reduction in lesion number and SUVmax at follow-up, indicating a metabolic response to therapy. However, persistent [18F]FDG uptake was observed in a subset of patients (3 out of 14). Median CRP levels declined from 12 mg/L (range: 0.3-190) at baseline to 3.6 mg/L (range: 0.9-20) at week 8 and remained low thereafter, broadly paralleling PET/CT findings. In several cases, residual metabolic activity did not result in treatment prolongation. Discussion: Serial [18F]FDG-PET/CT demonstrated changes in metabolic activity during treatment with reductions in lesion number and SUVmax in most patients. However, SUVmax reflects focal metabolic activity rather than total disease burden, and persistent uptake after the intensive treatment phase was observed in some patients. Larger prospective studies incorporating standardized response criteria and volumetric PET measures are needed before [18F]FDG-PET/CT can be implemented as a routine biomarker for treatment response in EPTB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.